Namibia
Tuberculosis profile
| High HIV burden |
Population  2013 2.3 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.3 (0.45–1.3) 57 (20–58)
Mortality (HIV+TB only) 2.1 (1.4–2.9) 90 (61–125)
Prevalence  (includes HIV+TB) 15 (8.2–24) 651 (357–1 031)
Incidence  (includes HIV+TB) 15 (13–17) 651 (566–742)
Incidence (HIV+TB only) 7.7 (5.4–9.9) 333 (236–430)
Case detection, all forms (%) 64 (56–74)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 3.8 (2.7–5.1) 16 (13–21)
MDR-TB cases among notified pulmonary
TB cases
250 (180–340) 360 (280–450)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 4 331   1 179
Pulmonary, clinically diagnosed 2 241   0
Extrapulmonary 1 846   0
       
Total new and relapse 9 597    
Previously treated, excluding relapses 1 013    
Total cases notified 10 610    
Among 9 432 new and relapse cases:
1 094 (12%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB      
Laboratory-confirmed RR-/MDR-TB cases     283
Patients started on MDR-TB treatment     170
TB/HIV 2013 Number (%)
TB patients with known HIV status 9 727 (92)
HIV-positive TB patients 4 343 (45)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 4 311 (99)
HIV-positive TB patients on antiretroviral therapy (ART) 3 491 (80)
HIV-positive people screened for TB 93 845  
HIV-positive people provided with IPT 15 795  
Treatment success rate (%)
New cases registered in 2012 85
Previously treated cases registered in 2012 78
HIV-positive TB cases, all types, registered in 2012 81
RR-/MDR-TB cases started on second-line treatment in 2011 59
XDR-TB cases started on second-line treatment in 2011 67
Laboratories 2013  
Smear (per 100 000 population) 1.3
Culture (per 5 million population) 2.1
Drug susceptibility testing (per 5 million population) 2.1
Sites performing Xpert MTB/RIF 4
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 34
% Funded domestically 36%
% Funded internationally 36%
% Unfunded 28%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-04 Data: www.who.int/tb/data